Can-Fite BioPharma (CANF) Competitors $1.20 -0.03 (-2.44%) Closing price 04:00 PM EasternExtended Trading$1.20 0.00 (0.00%) As of 05:50 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsHeadlinesOwnershipSEC FilingsTrendsBuy This Stock CANF vs. NAII, ENLV, PMN, RNXT, QTTB, GRCE, LSB, JATT, RLYB, and ANVSShould you be buying Can-Fite BioPharma stock or one of its competitors? The main competitors of Can-Fite BioPharma include Natural Alternatives International (NAII), Enlivex Therapeutics (ENLV), ProMIS Neurosciences (PMN), RenovoRx (RNXT), Q32 Bio (QTTB), Grace Therapeutics (GRCE), Lakeshore Biopharma (LSB), JATT Acquisition (JATT), Rallybio (RLYB), and Annovis Bio (ANVS). These companies are all part of the "pharmaceutical products" industry. Can-Fite BioPharma vs. Natural Alternatives International Enlivex Therapeutics ProMIS Neurosciences RenovoRx Q32 Bio Grace Therapeutics Lakeshore Biopharma JATT Acquisition Rallybio Annovis Bio Natural Alternatives International (NASDAQ:NAII) and Can-Fite BioPharma (NYSE:CANF) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their community ranking, earnings, analyst recommendations, valuation, risk, media sentiment, dividends, institutional ownership and profitability. Does the MarketBeat Community prefer NAII or CANF? Natural Alternatives International received 264 more outperform votes than Can-Fite BioPharma when rated by MarketBeat users. Likewise, 76.75% of users gave Natural Alternatives International an outperform vote while only 12.35% of users gave Can-Fite BioPharma an outperform vote. CompanyUnderperformOutperformNatural Alternatives InternationalOutperform Votes27476.75% Underperform Votes8323.25% Can-Fite BioPharmaOutperform Votes1012.35%Underperform Votes7187.65% Which has stronger valuation & earnings, NAII or CANF? Natural Alternatives International has higher revenue and earnings than Can-Fite BioPharma. Natural Alternatives International is trading at a lower price-to-earnings ratio than Can-Fite BioPharma, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioNatural Alternatives International$121.85M0.14-$7.22M-$1.29-2.09Can-Fite BioPharma$667K6.37-$7.63M-$1.79-0.67 Which has more volatility and risk, NAII or CANF? Natural Alternatives International has a beta of 0.6, suggesting that its stock price is 40% less volatile than the S&P 500. Comparatively, Can-Fite BioPharma has a beta of 1.37, suggesting that its stock price is 37% more volatile than the S&P 500. Do analysts prefer NAII or CANF? Can-Fite BioPharma has a consensus price target of $14.00, suggesting a potential upside of 1,066.67%. Given Can-Fite BioPharma's stronger consensus rating and higher probable upside, analysts plainly believe Can-Fite BioPharma is more favorable than Natural Alternatives International.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Natural Alternatives International 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Can-Fite BioPharma 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 1 Strong Buy rating(s) 3.33 Is NAII or CANF more profitable? Can-Fite BioPharma has a net margin of 0.00% compared to Natural Alternatives International's net margin of -6.26%. Can-Fite BioPharma's return on equity of 0.00% beat Natural Alternatives International's return on equity.Company Net Margins Return on Equity Return on Assets Natural Alternatives International-6.26% -9.36% -4.82% Can-Fite BioPharma N/A N/A N/A Does the media refer more to NAII or CANF? In the previous week, Can-Fite BioPharma had 4 more articles in the media than Natural Alternatives International. MarketBeat recorded 6 mentions for Can-Fite BioPharma and 2 mentions for Natural Alternatives International. Natural Alternatives International's average media sentiment score of 0.97 beat Can-Fite BioPharma's score of 0.28 indicating that Natural Alternatives International is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Natural Alternatives International 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Can-Fite BioPharma 1 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Do insiders and institutionals believe in NAII or CANF? 32.4% of Natural Alternatives International shares are held by institutional investors. Comparatively, 21.0% of Can-Fite BioPharma shares are held by institutional investors. 20.9% of Natural Alternatives International shares are held by insiders. Comparatively, 0.8% of Can-Fite BioPharma shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth. SummaryCan-Fite BioPharma beats Natural Alternatives International on 11 of the 19 factors compared between the two stocks. Remove Ads Get Can-Fite BioPharma News Delivered to You Automatically Sign up to receive the latest news and ratings for CANF and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CANF vs. The Competition Export to ExcelMetricCan-Fite BioPharmaPharmaceutical IndustryMedical SectorNYSE ExchangeMarket Cap$4.25M$6.45B$5.29B$18.43BDividend YieldN/A3.24%5.11%4.22%P/E Ratio-0.676.8821.7131.10Price / Sales6.37231.35379.1226.38Price / CashN/A65.6738.1517.54Price / Book0.685.916.434.30Net Income-$7.63M$142.72M$3.21B$1.02B7 Day Performance-14.16%7.98%5.23%2.90%1 Month Performance-27.27%-13.91%-9.53%-7.77%1 Year Performance-38.78%-9.98%10.99%2.31% Can-Fite BioPharma Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CANFCan-Fite BioPharma2.2959 of 5 stars$1.20-2.4%$14.00+1,066.7%-40.9%$4.25M$667,000.00-0.678Analyst ForecastGap DownNAIINatural Alternatives International1.5122 of 5 stars$3.12-5.7%N/A-57.7%$19.34M$121.85M-2.42290Short Interest ↓Gap UpENLVEnlivex Therapeutics3.3345 of 5 stars$0.89+0.2%$10.00+1,023.6%-40.7%$19.05MN/A-0.9170Short Interest ↓Positive NewsGap UpPMNProMIS Neurosciences3.008 of 5 stars$0.58-5.1%$6.00+929.7%-69.1%$19.05MN/A-5.835Positive NewsRNXTRenovoRx2.0199 of 5 stars$0.79-10.4%$6.00+659.5%-9.6%$18.96M$43,000.00-1.396Short Interest ↑News CoverageGap DownHigh Trading VolumeQTTBQ32 Bio2.3538 of 5 stars$1.53-6.7%$24.71+1,515.3%-92.6%$18.66M$-6,651,000.00-0.1139News CoverageGRCEGrace Therapeutics1.9494 of 5 stars$1.80-10.0%$12.00+566.7%N/A$18.25MN/A-1.55N/AGap DownLSBLakeshore Biopharma0.6733 of 5 stars$1.95-6.7%N/AN/A$18.15M$672.27M0.00773Upcoming EarningsShort Interest ↑News CoverageGap UpHigh Trading VolumeJATTJATT AcquisitionN/A$1.03-5.1%N/A-63.7%$17.77MN/A0.003High Trading VolumeRLYBRallybio2.421 of 5 stars$0.42-5.6%$9.75+2,194.7%-86.0%$17.68M$636,000.00-0.2740Analyst ForecastGap DownANVSAnnovis Bio1.453 of 5 stars$1.24-5.7%$37.00+2,896.0%-87.5%$17.58MN/A-0.283Gap Up Remove Ads Related Companies and Tools Related Companies Natural Alternatives International Alternatives Enlivex Therapeutics Alternatives ProMIS Neurosciences Alternatives RenovoRx Alternatives Q32 Bio Alternatives Grace Therapeutics Alternatives Lakeshore Biopharma Alternatives JATT Acquisition Alternatives Rallybio Alternatives Annovis Bio Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NYSE:CANF) was last updated on 4/17/2025 by MarketBeat.com Staff From Our Partners[Action Required] Claim Your FREE IRS Loophole GuideThis shouldn't surprise anyone who's been paying attention, but... Pres. Trump may be about to unleash the ...Colonial Metals | SponsoredGet Your Bank Account “Fed Invasion” Ready with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredAltucher: Turn $900 into $108,000 in just 12 months?We are entering the final Trump Bump of our lives. But the biggest returns will not be in the stock market.Paradigm Press | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowMy friends Joel and Adam have a simple motto: "For us, it's always a bull market." That’s because their 92%...Crypto Swap Profits | SponsoredElon Musk Confirms: Tesla’s Optimus is Replacing Workers… and Heading to MarsElon Musk just confirmed Tesla’s robot will go to Mars. But on Earth, it may trigger a trillion-dollar tech sh...InvestorPlace | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredTrump to redistribute trillions of dollars Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Can-Fite BioPharma Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share Can-Fite BioPharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy CANF Stock Free CANF Stock Alerts